Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TX103-CAR-T Cell Therapy in Recurrent Glioblastomas
NCT05241392Phase 1Active, not recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Jan 2022
- Primary completion
- Nov 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TX103-CAR-T in glioblastoma (GBM), sponsored by Beijing Tiantan Hospital. Primary endpoints: Dose Limiting Toxicity at 3 months and Adverse Events at 3 months. Started Jan 2022; status: active, not recruiting.
02
Drugs
TX103-CAR-T
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05241392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05241392.